Raha Pharmaceutical

What Raha Pharmaceutical does

Raha Pharmaceutical Co. (شرکت داروسازی رها) is a knowledge-based, privately-held Iranian generic pharmaceutical manufacturer headquartered in Isfahan. Founded in 1983 by Dr. Gholamreza Akhavan Farid, the company operates a 17,000 square meter GMP-certified facility housing 7 production lines that manufacture solid dosage forms (tablets, capsules, pellets), liquids (syrups, suspensions), injectables (ampoules), semi-solids, nasal sprays, and ophthalmic products. The company employs approximately 350 specialized staff and markets over 110 pharmaceutical products across 13+ therapeutic categories, including 20 products produced for the first time in Iran — notably Meglumine Antimoniate injection (third country globally after USA and France), controlled-release carbamazepine and sodium valproate, and ophthalmic formulations. Annual production exceeds 30 million units, generating over USD 30 million in foreign exchange savings for Iran through import displacement.

The company's business model is anchored in domestic pharmacy distribution via partner networks across Iran, with products registered in the national electronic prescription system (RXcode). Distribution channels include pharmacy networks, hospital and institutional supply, and an emerging export business covering Afghanistan (formal export contract) and Iraq (MOU with Rudin Pharmaceutical, 2024). The company pursues a sales-led go-to-market strategy, complemented by marketing channels centered on medical congress participation, CME sponsorship, and academic collaborations with Isfahan University of Medical Sciences and other institutions. Raha also engages in regulatory and government partnerships with Iran's Ministry of Health, Food and Drug Organization, and Chamber of Commerce to advance expansion plans. Diplomatic engagements with Cuba (2021), Thailand, and Yemen indicate intent to broaden export reach beyond current markets, although international sales remain a small fraction of total volume relative to the domestic Iranian market.

Name

Raha Pharmaceutical

Legal name

Raha Pharmaceutical Company (شرکت داروسازی رها)

Website

https://rahapharm.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

101–250 employees

Short description

Raha Pharmaceutical Co. is a privately-held Iranian generic drug manufacturer in Isfahan, operating 7 GMP-certified production lines to produce over 110 pharmaceutical products across 13 therapeutic categories, serving domestic pharmacy networks and emerging export markets including Afghanistan and Iraq.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Oral Solid Dose (OSD) Generics (HLAIABAD), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Controlled-release formulations
• Ophthalmic medications
• Injectable medications

Headquarters

HQ city

Isfahan

HQ country

Iran

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Domestic sales of generic pharmaceutical products across 13+ therapeutic categories through pharmacy networks and distribution partners across Iran.
2. Export and International Sales: Export of pharmaceutical products to Afghanistan and other international markets through trade agreements and partnerships.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Raha Pharmaceutical is a knowledge-based pharmaceutical manufacturer producing generic and branded generic pharmaceutical products across 13+ therapeutic categories. The company operates 7 GMP-certified production lines for tablets, capsules, syrups, ampoules, nasal sprays, eye drops, and semi-solid formulations at a 17,000 square meter facility in Isfahan, Iran, with over 110 marketed products and 20 first-in-Iran formulations.

Product overview

Raha Pharmaceutical is a knowledge-based pharmaceutical manufacturing company located in Isfahan, Iran, producing a diverse portfolio of generic and branded medications across multiple therapeutic categories. The company operates 7 production lines covering tablets, capsules, syrups, ampoules, nasal sprays, eye drops, and semi-solid formulations. Product portfolio includes cardiovascular medications (Amiohart), ophthalmic products (Hyalura, Timolin-B, Lotra), neurological/psychiatric drugs (Alpic, various CNS medications), dermatological products (Clobetasol), hepatoprotective supplements (Rahasil), and comprehensive nutritional supplements (Santom Silver, Ravit-B, Ravita-C). The company has introduced innovative products including Meglumine Antimoniate ampoule (first production in Iran) for leishmaniasis treatment, and sustained-release formulations for improved drug delivery. Distribution spans through pharmacies and distribution partners across Iran with export activities to Afghanistan, Iraq, and other regional markets.

Differentiator

Problem solved

Functional benefit

Brands

• Raha: Main pharmaceutical brand for generic medications including cardiovascular, neurological, and gastrointestinal products
• Ravit-B
• Ravita-C
• Sentom Silver
• Clobetasol

Products and services

• Hyalura Eye Drops (Artificial Tears)
• Ibuprofen Suspension
• Tranexamic Acid Ampoule
• Amiohart (Amiodarone) Ampoule
• Rahasil Tablet
• Timolin-B Eye Drops (Timolol + Brimonidine)
• Clobetasol Cream 0.05%
• Ravit-B Tablet (B Vitamins + Vitamin C + Calcium)
• Ravita-C Tablet (Zinc + Vitamins E, D, A, C)
• Santom Silver Tablet (Multivitamin + Mineral)
• Alpic Capsule (Alpha Lipoic Acid)
• Meglumine Antimoniate Ampoule
• Lotra 0.5% Eye Drops (Loteprednol Etabonate)
• Potassium Citrate SR 1080mg Tablet
• Tegretard 400 (Carbamazepine Controlled Release)
• RahaKin 500 (Sodium Valproate Controlled Release)

Quantifiable outcome

• Over 30 million USD annual foreign exchange savings for Iran through domestic production
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Iran Food and Drug Organization (Ministry of Health)coreOthers · 6 September 1404Deputy Minister of Health and Head of Food and Drug Organization, Dr. Mehdi Pir Salehi, and Director General of Drug Affairs visited Raha's production lines and discussed new drug development programs and future expansion plans.
• Isfahan Chamber of CommercecoreChannel Partner/ Reseller/ Distributor · 8 August 1404Coordinated visit by Isfahan Chamber of Commerce delegation to explore production capabilities, quality control, and R&D facilities. Discussions focused on export opportunities and digital service capabilities.
• Afghanistan Healthcare BuyerscoreChannel Partner/ Reseller/ Distributor · 20 December 1403Sales and export contract for pharmaceutical products to Afghanistan, marking Raha's entry into the Afghan pharmaceutical market.
• Rudin Pharmaceutical (Iraq)coreChannel Partner/ Reseller/ Distributor · 4 October 1403Second meeting between Raha's export team and Iraqi delegation resulted in signing of an MOU with Rudin Pharmaceutical for marketing and sales of Raha's pharmaceutical products in Iraq.
• Isfahan University of Medical SciencescoreStrategic or Co-development PartnerStrong academic collaboration including student visits, educational sessions, lectures by the CEO at the School of Pharmacy, and joint programs for medical and pharmacy students.
• Isfahan University of TechnologyminorStrategic or Co-development PartnerAcademic visit by the university president and Science and Technology Park representatives to explore technological collaboration and research partnerships.
• Kerman University of Medical SciencesminorStrategic or Co-development PartnerPharmacy students from Kerman visited Raha's manufacturing facilities and learned about production and quality processes.
• Hamadan University of Medical SciencesminorStrategic or Co-development PartnerPharmacy students from Hamadan visited Raha's facilities to learn about research, production, and quality control processes.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Cipla Limited: Major Indian generic pharmaceutical manufacturer with a broad finished-dosage-form portfolio across emerging markets. Comparable as a generic pharmaceutical manufacturer with multi-format production capabilities and emerging-market distribution focus.
• Dr. Reddy's Laboratories: Global generic and specialty pharmaceutical manufacturer with strong emerging-market footprint across multiple dosage forms. Comparable as a large-scale generic finished dosage form producer with export-oriented GTM to underserved markets.

Direct peers

• Darou Pakhsh Pharmaceutical Manufacturing Company: Iran's largest pharmaceutical manufacturer producing generics across tablets, injectables, and sterile formats with multiple GMP-certified lines. Directly comparable as a domestic Iranian generic manufacturer serving the same pharmacy network and formulary.
• Barakat Pharmaceutical Company: Iranian state-affiliated generic pharma manufacturer producing a broad portfolio of finished dosage forms. Comparable as a domestic Iranian competitor in generic pharmaceutical manufacturing with knowledge-based positioning.
• Actoverco Pharmaceutical: Iranian pharmaceutical manufacturer producing generics across solid and liquid dosage forms with GMP-certified facilities. Directly comparable manufacturing footprint, generic portfolio, and domestic distribution through pharmacy channels.
• Alborz Darou Pharmaceutical: Iranian pharmaceutical manufacturer producing tablets, capsules, injectables, and other finished dosage forms. Closely comparable as a domestic generic pharma competitor operating GMP-certified production lines.
• Tofigh Darou Pharmaceutical Company: Iranian generic pharmaceutical manufacturer producing tablets, capsules, syrups, and injectables with GMP certification. Closely comparable dosage-form breadth, distribution model through Iranian pharmacy networks, and generic-pharma positioning.

Regional players

• Abidi Pharmaceuticals: Iranian pharmaceutical manufacturer producing generic finished dosage forms including tablets, capsules, and injectables. Comparable domestic Iranian generic peer with multi-format manufacturing capabilities.
• Sobhan Oncology: Iranian specialty pharmaceutical company focused on oncology and hospital injectables. Comparable as a domestic Iranian pharma manufacturer with specialty injectable capabilities and hospital-channel distribution.
• Karen Pharmaceutical Company: Iranian pharmaceutical manufacturer producing generic medications across multiple therapeutic categories and dosage forms. Comparable as a domestic Iranian competitor in generic finished dosage form manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/rahapharm
• LinkedInlinkedin.com/company/rahapharmaco

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Raha Pharmaceutical